Rare Partners is a non profit company devoted to the development of new therapies and diagnostics in the field of rare diseases.
FDA grants Orphan Drug Designation for the use of teicoplanin in Staphylococcus aureus infections in cf patients.
Wellcome Trust supports the development of sirolimus in beta - thalassemia, a collaborative project between Rare Partners and Ferrara University
Sirolimus has been granted Orphan Drug Designation for the treatment of sickle cell disease also in USA
